ReviewCancers2024
Inflammatory Bowel Disease and Colorectal Cancer.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- IBD-related inflammatory memory and colorectal cancer: epigenetic mechanisms and microbiome interventions.Frontiers in immunology · 2026Pooled it
- Dietary inflammatory index and the risk of colorectal adenomas and cancer: a systematic review and dose-response meta-analysis.Nutrition journal · 2025Pooled it
- Association between inflammatory bowel disease and the risk of liver cancer: a systematic review and meta-analysis.Clinical and experimental medicine · 2025Pooled it
- Is the oral pathogen, Porphyromona gingivalis, associated to colorectal cancer?: a systematic review.BMC cancer · 2025Pooled it
- Merkel Cell Polyomavirus in colorectal cancer: exploring the Wnt/β-catenin pathway.Virus research · 2026Article
- Infrared spectroscopy with statistical analysis and machine learning for cancer risk assessment in inflammatory bowel disease patients.The Analyst · 2026Article
- A High Sensitivity and Anti-Scaling Surface Plasmon Resonance Sensor for Early Screening of Colorectal Cancer.Biosensors · 2026Article
- Review
- Review
- Circulating tRF-Gly-GCC as a biomarker for colorectal cancer and Crohn's disease activity.Scientific reports · 2026Article
- Beyond the Intestinal Mucosa in Long-Standing Inflammatory Bowel Disease: Consequences of Chronic Inflammation and Endoscopic Approaches to Diagnosis and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Organ Preservation After Total Neoadjuvant Therapy in a Patient With Low Rectal Adenocarcinoma and Crohn's Disease.ACG case reports journal · 2026Article
- Deciphering immune and cellular reprogramming during the progression from inflammatory bowel disease to colorectal cancer using multi-omics single-cell and spatial transcriptomics.Journal of translational medicine · 2026Article
- Anti-Inflammatory Effects ofFood science & nutrition · 2026Article
- Oral delivery of engineeredMaterials today. Bio · 2026Article
- Serum Cytokine Profiles Associated with Inflammation and Tumor Progression in Crohn's Disease and Colorectal Cancer.International journal of molecular sciences · 2026Article
- Challenges and Prospects of Using Novel Nonlinear Effects in Multimode Optical Fibers for Multiphoton Endomicroscopy.Diagnostics (Basel, Switzerland) · 2026Review
- Unraveling gene interaction networks in colorectal cancer and inflammatory bowel disease via a novel hybrid radial basis function network.Scientific reports · 2026Article
- The gut microbiome in colorectal cancer: mechanisms of carcinogenesis and emerging microbiota-targeted therapies.Discover oncology · 2026Review
- Clostridioides difficile : A suspected pro-carcinogenic bacterium for gastrointestinal tumors.Chinese medical journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with inflammatory bowel diseases (IBDs), including both ulcerative colitis (UC) and Crohn's disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, integrated surveillance programs, and improved medical therapies have led to a decrease in the incidence of CRC among IBD patients. Currently, the management of patients with IBD who have a history of or ongoing active malignancy is an unmet need. This involves balancing the risk of cancer recurrence/progression with the potential exacerbation of IBD if the medications are discontinued. The objective of this review is to provide an updated summary of the epidemiology, causes, risk factors, and surveillance approaches for CRC in individuals with IBD, and to offer practical guidance on managing IBD patients with history of previous or active cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.